Alternative use for hydrogel intrasaccular occlusion device with an umbrella member for structural support
The present disclosure relates to the field of endovascular treatment. More particularly, the present invention uses a modified hydrogel intrasaccular occlusion device designed to implement an endovascular treatment to ameliorating or eliminating aneurysm recurrence, which hydrogel may optionally be impregnated with pharmaceutical compounds. The present invention also teaches the use of thin hydrogel coatings to ameliorate endovascular treatment related difficulties.
1. A device for ameliorating aneurysm recurrences by deploying amorphous hydrogel; said device further including:
a treatment mesh,
wherein said treatment mesh further includes at least one reinforcement element comprising a telescoping center-support bar, wherein said telescoping center-support bar further includes umbrella-like radial support struts; and
wherein said amorphous hydrogel is affixed to said telescoping center-support bar, and said umbrella-like radial support structures,
wherein said at least one reinforcement element minimizes risk of collapse.
2. The device of claim 1 , wherein said amorphous hydrogel is impregnated with pharmaceutical compounds.
3. The device of claim 1 , wherein said device comprises a thin coating of said amorphous hydrogel on any surface exposed to blood or a lumen wall.
4. A device for ameliorating vascular outpouchings by deploying amorphous hydrogel; said device further including:
a treatment mesh,
wherein said treatment mesh further includes at least one reinforcement element comprising a telescoping center-support bar, wherein said telescoping center-support bar further includes umbrella-like radial support struts; and
wherein said amorphous hydrogel is affixed to said telescoping center-support bar, and said umbrella-like radial support structures,
wherein said at least one reinforcement element minimizes risk of collapse.
5. The device of claim 4 , wherein said amorphous hydrogel is impregnated with pharmaceutical compounds.
6. The device of claim 4 , wherein said device comprises a thin coating of said amorphous hydrogel on any surface exposed to blood or a lumen wall.